9th Annual Biomarkers Congress

View Profile


Clinical Trial Activity

Start year End year Protocols Investigators Notes
1. 2009 Randomized Phase II Study of Whole Brain Radiation Alone (WBRT), WBRT with Sorafenib, or WBRT with Sunitinib® for the Treatment of Patients with Brain Metastases from Non-Small Cell Lung Cancer Deepak Khuntia and Adam Dicker
2. 2009 Towards customized radiation dose escalation strategies for prostate cancer Benjamin W. Corn, George Iliakis, co-principal investigators, Leonard Gomella, Richard K. Valicenti, Adam P. Dicker, MD PhD co-investigators
3. 2009 Evaluation of Radioactive Seed Implants in the Prostate Gland with 3-D Ultrasound. Ethan Halpern principal investigator, Adam P. Dicker, MD PhD
4. 2009 Stents and Radiation Therapy Trial Adam P. Dicker MD, PhD, coinvestigator, Sponsor Novoste
5. 2009 Evaluation of Radioactive Seed Implants in the Prostate Gland with Ultrasound. Adam P. Dicker, MD, PhD
6. 2009 Survey about the use of e-mail communication by doctors and patients Adam P. Dicker, M.D., Ph.D
7. 2009 Active breathing control to reduce actual tumor volume in radiotherapy treatment planning for lung cancer. Principal investigator-Maria,Werner-Wasik, M.D, Adam P. Dicker, M.D., Ph.D., Sub-investigator
8. 2009 A Phase II Study of Bicalutamide Adam P. Dicker, M.D., Ph.D., principal investigator- Jefferson Oncology Group
9. 2009 Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) expression in human meningioma and pituitary adenoma Adam P. Dicker, M.D., Ph.D., Co-investigator: Lawrence Kenyon, M.D., Ph.D
10. 2009 A Phase I Study of Combination Chemoradiotherapy with Biologic Therapy fo Advanced Head and Neck Cancerr Mitchell Machtay, Adam Dicker-sub PI, Rita Axelroad
11. 2009 A Phase I Study of ZD1839 (Iressa) and Hypofractionated Thoracic Radiotherapy Maria Werner-Wasik, MD, Adam Dicker, MD, PhD
12. 2009 BRAVO-Beta radiation for the treatment of arterial venous outflow Adam Dicker
13. 2009 University of Wisconsin-Phase II Study of Rofecoxib For the Treatment of Glioma Associated Edema Behnam Badie, M.D., and Joseph J. Merchant. M.D, H. Ian Robins, M.D., Ph.D, Minesh P. Mehta, M.D., Victor Haughton, M.D., Jason P. Fine, Ph.D., Adam P. dicker MD, Phd
14. 2009 A phase I, single-center, open-label dose-escalation, safety, pharmcokinetic, and pharmacodynamic study of intravenously administered recombinant human angiostatin in cancer patients. Walter J. Curran, Jr., M.D, Robert Capizzi, M.D., Eduardo DeMoraes, M.D. Kendra Seeney, M.D., Adam P. Dicker, Derrick Grant, Ph.D
15. 2009 A phase I, single-center, open-label dose-escalation, safety, and pharmacodynamic, study of the combination of intravenously administered recombinant human angiostatin protein and radiation therapy for the treatment of patients with cancer. Walter J. Curran, Jr., M.D. Principal Investigator, Adam P. Dicker, M.D., Ph.D. Co-PI, Pramila Rani Anne, M.D., Jorge Freire, M.D., Lydia Komarnicky, M.D., Bruce Turner, M.D., Ph.D., Kelly Underhill, M.D., Richard, Valicenti, M.D., Maria Werner-Wasik, M.D. sub-investigators
16. 2009 A Phase I Study using Epothilone B Adam P. Dicker, M.D., Ph.D
17. 2009 A phase I, open-label, dose-escalation PI-Adam P. Dicker
18. 2009 A phase I, open-label PI-Adam P. Dicker.
19. 2009 Phase I, study of the combination of Sorafenib and radiation therapy for the treatment of patients with brain metastases and primary brain tumors PI-Adam P.Dicker.
20. 2009 Organ displacement after radical prostatectomy Adam P. Dicker MD PhD and Benjamin W. Corn
21. 2009 Radiation Therapy Oncology Group Phase II study of conventional radiation therapy plus squalamine for supratentorial blioblastoma. Adam P. Dicker, M.D., Ph.D
22. 2009 Radiation Therapy Oncology Group, (RTOG 0128) Phase I/II study of COX-2 inhibitor, CELEBREXâ„¢ (CELECOXIB), radiation, and cisplatin in patients with locally advanced cervical cancer. David Gaffney, M.D., Ph.D. and Adam P. Dicker
23. 2009 Radiation Therapy Oncology Group, RTOG 0217, A phase II study of an oral Farnesyl Transferase Inhibitor (FTI) R115777 (NSC#702818) with radiation therapy in glioblastoma multiforme Ian Robins, MD and Adam P. Dicker
24. 2009 Radiation Therapy Oncology Group, RTOG 0417, A Phase II Study of Bevacizumab in Combination with Definitive Radiotherapy and Cisplatin Chemotherapy in Untreated Patients with Locally Advanced Cervical Carcinoma. Tracy Schefter MD, Janice S. Kwon MD, Adam Dicker MD, PhD
25. 2009 RTOG 0539, PHASE II TRIAL OF OBSERVATION FOR LOW-RISK MENINGIOMAS AND OF IMRT FOR INTERMEDIATE- AND HIGH-RISK MENINGIOMAS. C. Leland Rogers MD and Adam P. Dicker, M.D., Ph.D., Michael Vogelbaum, MD, PhD, Arie Perry, MD, Lynn Ashby, MD.
26. 2009 Radiation Therapy Oncology Group RTOG 0436. A phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer who are treated with without surgery. Mohan Suntharalingam, MD, David Ilson MD PhD, Adam P. Dicker MD, PhD.
27. 2009 Radiation Therapy Oncology Group, RTOG 0622, phase II trial of Samarium 153 followed by salvage prostatic fossa 3DCRT or IMRT irradiation in high-risk, clinically non-metastatic prostate cancer after radical prostatectomy. Richard K. Valicenti, M.D., M.A., Edouard J. Trabulsi, M.D., Oliver A. Sartor, M.D, Joann Prisciandaro, PhD., DABR, Adam P. Dicker, MD, PhD.
28. 2009 Radiation Therapy Oncology Group, RTOG 0811. A randomized phase II study of radiation therapy (IMRT) +/- cetuximab (C225) for intermediate risk resected head and neck cancer M. Machtay, PI, L. Siu, Adam P. Dicker, S. Breen, G. Bednarz, C. Holsinger.
29. 2009 Radiation Therapy Oncology Group, RTOG 0839. Phase II study of pre-operative chemoradiotherapy + cetuximab followed by consolidation chemotherapy + cetuximab in resectable and unresectable locally advanced non-small cell lung cancer. Martin Edelman, PI, C-Chairs; Quynh Thu Le, Jessica Donington, Adam P Dicker
30. 2009 Randomized Phase II Trial of IMRT or Concurrent Sunitinib Malate (SU 11248)/ IMRT as Treatment for Recurrent Glioblastoma Multiforme. Proposed trial to RTOG. Christina Tsien and Adam Dicker
31. 2008 Phase I, study of the combination of Vorinostat a histone deacetylation inhibitor (HDAC) and radiation therapy for the treatment of patients with brain metastases. PI-Adam P.Dicker.


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.